20:29 , Dec 16, 2016 |  BC Week In Review  |  Company News

Adcetris sales and marketing update

The U.K.’s NICE issued draft guidance recommending against the use of Adcetris brentuximab vedotin from Takeda to treat CD30-positive Hodgkin’s lymphoma. Specifically, the agency recommends against Adcetris’ use for patients with relapsed or refractory disease...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

CAR-T CD30: Phase I data

Data from 7 evaluable patients with relapsed and refractory Hodgkin’s lymphoma in an open-label, Chinese Phase I trial showed that CAR-T CD30 led to an objective response rate (ORR) of 28.6% and a disease control...